What is Retatrutide?

Retatrutide is a research peptide in the GLP-1 Metabolic class. Triple agonist: GLP-1, GIP, and glucagon receptor. It is studied at per-dose ranges of 0.5–12 mg / week (0.5–12 mg weekly), administered weekly sc over cycles of research phase. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Triple-agonist peptide showing dose-dependent weight reduction in Phase 2. Glucagon component drives additional energy expenditure.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Retatrutide work?

Primary mechanism: Triple agonist: GLP-1, GIP, and glucagon receptor. Research on Retatrutide implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for Retatrutide remain areas of active investigation; several proposed effects within the GLP-1 Metabolic class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Retatrutide dosage & protocol

Reference protocol for Retatrutide (research context only, drawn from published literature):

  • Per dose: 0.5–12 mg / week
  • Weekly total: 0.5–12 mg
  • Frequency: Weekly SC
  • Cycle: Research phase

Stacking Retatrutide

Commonly referenced pairing with Retatrutide: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Retatrutide stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Unestablished safety profile. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Retatrutide — common questions

What is Retatrutide and what is it used for in research?
Retatrutide is classified within the GLP-1 Metabolic group. Triple-agonist peptide showing dose-dependent weight reduction in Phase 2. Glucagon component drives additional energy expenditure. Research applications focus on the pathways outlined below. All references on this page describe published research only — Retatrutide is supplied for in-vitro and laboratory use, not for human consumption.
How does Retatrutide work?
Primary mechanism: Triple agonist: GLP-1, GIP, and glucagon receptor. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Retatrutide remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Retatrutide research dose?
Published research protocols for Retatrutide describe per-dose ranges of 0.5–12 mg / week, with a weekly total near 0.5–12 mg, administered weekly sc. Typical cycle: research phase. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Retatrutide in Thailand?
Retatrutide is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Retatrutide be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, phase 2 trial. Lancet. 2023. PMID: 37385280

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.